• Je něco špatně v tomto záznamu ?

Parallel DNA/RNA NGS Using an Identical Target Enrichment Panel in the Analysis of Hereditary Cancer Predisposition

P. Kleiblová, M. Černá, P. Zemánková, K. Matějková, P. Nehasil, J. Hojný, K. Horáčková, M. Janatová, J. Soukupová, B. Šťastná, Z. Kleibl

. 2024 ; 70 (1) : 62-73. [pub] -

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24009801

Grantová podpora
NU23-03-00150 Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN 64165 Ministerstvo Zdravotnictví Ceské Republiky
SVV 260516 Univerzita Karlova v Praze
LX22NPO5102 Ministerstvo Školství, Mládeže a Tělovýchovy

Germline DNA testing using the next-gene-ration sequencing (NGS) technology has become the analytical standard for the diagnostics of hereditary diseases, including cancer. Its increasing use places high demands on correct sample identification, independent confirmation of prioritized variants, and their functional and clinical interpretation. To streamline these processes, we introduced parallel DNA and RNA capture-based NGS using identical capture panel CZECANCA, which is routinely used for DNA analysis of hereditary cancer predisposition. Here, we present the analytical workflow for RNA sample processing and its analytical and diagnostic performance. Parallel DNA/RNA analysis allowed credible sample identification by calculating the kinship coefficient. The RNA capture-based approach enriched transcriptional targets for the majority of clinically relevant cancer predisposition genes to a degree that allowed analysis of the effect of identified DNA variants on mRNA processing. By comparing the panel and whole-exome RNA enrichment, we demonstrated that the tissue-specific gene expression pattern is independent of the capture panel. Moreover, technical replicates confirmed high reproducibility of the tested RNA analysis. We concluded that parallel DNA/RNA NGS using the identical gene panel is a robust and cost-effective diagnostic strategy. In our setting, it allows routine analysis of 48 DNA/RNA pairs using NextSeq 500/550 Mid Output Kit v2.5 (150 cycles) in a single run with sufficient coverage to analyse 226 cancer predisposition and candidate ge-nes. This approach can replace laborious Sanger confirmatory sequencing, increase testing turnaround, reduce analysis costs, and improve interpretation of the impact of variants by analysing their effect on mRNA processing.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24009801
003      
CZ-PrNML
005      
20250110125108.0
007      
ta
008      
240606s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.14712/fb2024070010062 $2 doi
035    __
$a (PubMed)38830124
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kleiblová, Petra $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. pekleje@lf1.cuni.cz $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. pekleje@lf1.cuni.cz $7 xx0125463
245    10
$a Parallel DNA/RNA NGS Using an Identical Target Enrichment Panel in the Analysis of Hereditary Cancer Predisposition / $c P. Kleiblová, M. Černá, P. Zemánková, K. Matějková, P. Nehasil, J. Hojný, K. Horáčková, M. Janatová, J. Soukupová, B. Šťastná, Z. Kleibl
520    9_
$a Germline DNA testing using the next-gene-ration sequencing (NGS) technology has become the analytical standard for the diagnostics of hereditary diseases, including cancer. Its increasing use places high demands on correct sample identification, independent confirmation of prioritized variants, and their functional and clinical interpretation. To streamline these processes, we introduced parallel DNA and RNA capture-based NGS using identical capture panel CZECANCA, which is routinely used for DNA analysis of hereditary cancer predisposition. Here, we present the analytical workflow for RNA sample processing and its analytical and diagnostic performance. Parallel DNA/RNA analysis allowed credible sample identification by calculating the kinship coefficient. The RNA capture-based approach enriched transcriptional targets for the majority of clinically relevant cancer predisposition genes to a degree that allowed analysis of the effect of identified DNA variants on mRNA processing. By comparing the panel and whole-exome RNA enrichment, we demonstrated that the tissue-specific gene expression pattern is independent of the capture panel. Moreover, technical replicates confirmed high reproducibility of the tested RNA analysis. We concluded that parallel DNA/RNA NGS using the identical gene panel is a robust and cost-effective diagnostic strategy. In our setting, it allows routine analysis of 48 DNA/RNA pairs using NextSeq 500/550 Mid Output Kit v2.5 (150 cycles) in a single run with sufficient coverage to analyse 226 cancer predisposition and candidate ge-nes. This approach can replace laborious Sanger confirmatory sequencing, increase testing turnaround, reduce analysis costs, and improve interpretation of the impact of variants by analysing their effect on mRNA processing.
650    _2
$a lidé $7 D006801
650    12
$a genetická predispozice k nemoci $7 D020022
650    12
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a nádory $x genetika $x diagnóza $7 D009369
650    _2
$a RNA $x genetika $7 D012313
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a sekvenční analýza DNA $x metody $7 D017422
650    _2
$a sekvenční analýza RNA $x metody $7 D017423
650    _2
$a DNA $x genetika $7 D004247
655    _2
$a časopisecké články $7 D016428
700    1_
$a Černá, Marta $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0239559
700    1_
$a Zemánková, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0239540
700    1_
$a Matějková, Kateřina $u Department of Genetics and Microbiology, Faculty of Science, Charles University, Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Nehasil, Petr $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic $7 _AN117368
700    1_
$a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0233403
700    1_
$a Horáčková, Klára $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Janatová, Markéta $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 stk2008428924
700    1_
$a Soukupová, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0239539
700    1_
$a Šťastná, Barbora $u Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Kleibl, Zdeněk, $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $d 1969- $7 jo2003183974
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 70, č. 1 (2024), s. 62-73
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38830124 $y Pubmed
910    __
$a ABA008 $b A 970 $c 89 $y p $z 0
990    __
$a 20240606 $b ABA008
991    __
$a 20250110125101 $b ABA008
999    __
$a ok $b bmc $g 2247166 $s 1219631
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 70 $c 1 $d 62-73 $e - $i 0015-5500 $m Folia biologica $n Folia Biol (Praha) $x MED00011004
GRA    __
$a NU23-03-00150 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a RVO-VFN 64165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a SVV 260516 $p Univerzita Karlova v Praze
GRA    __
$a LX22NPO5102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$b NLK138 $a Pubmed-20240606

Najít záznam

Citační ukazatele

Možnosti archivace